Mutation-specific cancer therapy has shown promising clinical efficacy. In non–small-cell
lung cancer (NSCLC), the presence of mutations in the epidermal growth factor receptor …

Mutations in the ERBB2 gene were recently found in approximately 2% of primary non-small
cell lung cancer (NSCLC) specimens; however, little is known about the functional …

Oncogenic alterations in human epidermal growth factor receptor 2 (HER2) occur in
approximately 2% of patients with non-small cell lung cancer and predominantly affect the …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are
effective treatments for a subset of non–small cell lung cancers. In particular, cancers with …

Recent efforts to comprehensively characterize the mutational landscape of non-small cell
lung cancer have identified frequent mutations in the receptor tyrosine kinase ERBB4 …

Inhibitors targeting the epidermal growth factor receptor (EGFR) are effective in a subset of
non–small cell lung cancers. Such cancers often harbor EGFR mutations and/or …

Oncogenic driver mutations identified in non-small cell lung cancer (NSCLC) have triggered
the development of drugs capable of interfering in intracellular signaling pathways involved …

HER3 and mutant EGFR meet MET | Nature Medicine Skip to main content Thank you for
visiting nature.com. You are using a browser version with limited support for CSS. To obtain the …

Introduction Erb-b2 receptor tyrosine kinase 2 gene (ERBB2)(also called HER2) has long
been recognized as an oncogenic driver in some breast and gastroesophageal cancers in …

In-frame insertions in exon 20 of HER2 are the most common HER2 mutations in patients
with non–small cell lung cancer (NSCLC), a disease in which approved EGFR/HER2 …